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ABSTRACT
Approximately 12% of postmenopausal women have osteoporotic vertebral fractures (VFs); these are associated with excess morbidity
andmortalityandahighriskoffutureosteoporoticfractures.Despitethis,lessthanone-thirdcometoclinicalattention,partlyduetolack
of clear clinical triggers for referral for spinal radiographs. The aim of this study was to investigate whether a novel primary care–based
screening tool could be used to identify postmenopausal women with osteoporotic VFs and increase appropriate management of
osteoporosis. A randomized controlled trial was undertaken in 15 general practices within the Bristol area of the UK. A total of 3200
womenaged65to80yearswereenrolled,withnoexclusioncriteria.Asimplescreeningtoolwascarriedoutbyanurseinprimarycareto
identify women at high risk of osteoporotic VFs. All identified high-risk women were offered a diagnostic thoracolumbar radiograph.
Radiographs were reported using standard National Health Service (NHS) reporting, with results sent back to each participant’s general
practitioner (GP). Participants in the control arm did not receive the screening tool or radiographs. The main outcome measure was self-
reported prescription of medication for osteoporosis at 6 months with a random 5% subsample verified against electronic GP records.
Secondary outcome was self-reported incidence of new fractures. Results showed that allocation to screening increased prescription of
osteoporosis medications by 124% (odds ratio [OR] for prescription 2.24 at 6 months; 95% confidence interval [CI], 1.16 to 4.33).
Allocation to screening also reduced fracture incidence at 12-month follow-up (OR for new fracture 0.60; 95% CI, 0.35–1.03; p¼0.063),
although this did not reach statistical significance. This study supports the use of a simple screening tool administered in primary care to
increase appropriate prescription of medications for osteoporosis in postmenopausal women in the UK.  2012 American Society for
Bone and Mineral Research.
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Introduction
O
steoporosis is one of the most common diseases affecting
elderly women. One of the most serious consequences of
osteoporosis is vertebral fractures (VFs), which are common: data
from the European Vertebral Osteoporosis Study (EVOS) suggest
that 6% to 21% of postmenopausal women have at least one
vertebral deformity, the majority of which will be osteoporotic
in origin, with an average prevalence of 12%.
(1) These 12% of
women have a reduced quality of life,
(2) functional limitations
including respiratory compromise,
(3) a modest excess mortality,
(4)
and immediate costs to health care providers of between
$2000
(5) and $7300.
(6) Perhaps most important, they are at high
risk of further vertebral
(7) and other osteoporotic fractures.
(8)
However, if these undiagnosed women were prescribed
appropriate osteoporosis medications, then expected further
fractures could be reduced by between 20% and 50%.
(9,10)
Despite this, less than one-third of osteoporotic VFs come to
clinical attention.
(11) Possible explanations include inaccurate
reporting of spinal radiographs and failure of appropriate
recognition and coding of radiograph reports in primary care.
However, the probable major reason for this diagnostic failure
is that there is lack of awareness of clinical triggers for referral
for diagnostic spinal radiographs in patients with possible VFs.
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664General practitioners (GPs) are generally dissuaded from
referring patients for radiographs in the UK, and without
accurateclinicalindicatorsforprevalentVFs,thegreatmajorityof
patients are likely to remain undiagnosed until presenting with
late clinical sequelae.
We previously carried out a population-based cross-sectional
study to define clinical risk factors for identifying women at high
risk of prevalent VFs, to serve as a preselection tool for spinal
radiographs.
(12) In that study we examined associations between
the presence of VF and risk factors for VF ascertained from
‘‘hands-on’’ assessment by a nurse, in 509 women 65 to 75 years
old recruited from general practices in southwest UK. Receiver
operating characteristic (ROC) curves suggested that the model
for predicting more than one VF may have diagnostic utility,
in light of predictive values of 0.88 (0.80–0.97). Using a threshold
offour,good separationofosteoporosis riskscores wasobserved
according to the presence orabsence of more than one VF. If this
threshold had been applied to the original population in order
to preselect patients for radiographs, this would have reduced
the number of X-ray referrals by approximately 70%, while
identifying one-half of those with one VF and nearly all of
those with more than one VF. We postulated that these four
independent clinical predictors could be used as a simple
screening tool for identifying women at high risk of more than
one VF in a population-based setting.
The aim of this pragmatic randomized controlled trial (RCT)
based on the Cohort for Skeletal Health in Bristol and Avon
(COSHIBA), which was specifically recruited for this purpose, was
to investigate if this simple screening tool would appropriately
increase the prescription of medications for osteoporosis. This
primary outcome measure was chosen as a proxy for reduction
in fracture incidence: although fracture occurrence was also
examined, this was specified as a secondary outcome due to our
limited power to detect a reduction in fracture risk as measured
directly.
Patients and Methods
The trial was run from the University of Bristol and recruited
participants from multiple general practices within the Bristol
area of the UK. Practices that took part in the original pilot were
not recruited. Ethics approval was obtained from the National
Research Ethics Service (REC reference number 07/Q2005/47),
and all study participants provided written consent. The study
protocol was registered with ClinicalTrials.gov (NCT00463905).
The study was funded by the Arthritis Research UK via a Clinician
Scientist Fellowship for the principal investigator (E.C.).
Recruitment of study participants and baseline
assessment
Thirty general practices were approached to take part in this
study and 15 agreed (Fig. 1). Information was provided to all
participating general practices on appropriate management
of prevalent VFs. As described previously,
(13) these general
practices were from a range of neighborhoods and deprivation
scores. Eligibility criteria for individual participants was being
female and having a date of birth between January 1, 1927 and
December 31, 1942. There were no exclusion criteria, although
someprimarycarephysiciansdidnotinvitewomentheythought
were unsuitable (such as those with serious illness or cognitive
impairment). Baseline data collection was by self-completion of
questionnaires prior to randomization. Wording of questions has
previously been described.
(13)
30 GP prac ces invited from Bristol area
15 prac ces recruited
1144 too ill or not appropriate 
according to GP
8224 eligible women
7080 invited
3200 (38.9% of eligible, 45.2% of invited) enrolled 
with baseline data collec on
2138 randomised to control arm 1062 randomised to interven on arm
Interven on: healthy bones informa on leaﬂet Interven on: healthy bones informa on leaﬂet plus 
Apply screening tool (n=983, 92.6%) 1.
Oﬀer X-ray to those at risk (n=401, 40.8% of  2.
assessed)
79 DNA screening
91 did not have X-ray
6-months follow-up:
n=1941 (90.8%) in control arm
n=979 (92.2%) in interven on arm
280 (8.8%) lost to follow-up
12-months follow-up:
n=1920 (89.8%) in control arm
n=959 (90.3%) in interven on arm
321 (10.0%) lost to follow-up
Fig. 1. Flow diagram of the trial process based on the CONSORT statement 2010.
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Data collected included osteoporosis medications prescribed at
point of entry to study, traditional risk factors for osteoporosis
such as personal and family history of hip fracture, previous
fracture after age 50 years, smoking, early menopause, oral
corticosteroids for more than 3 months, and number of falls over
the previous 5 years. Highest education achieved qualification
was categorized into none/basic matriculation, vocational,
O-levels or equivalent, A-levels or equivalent, or university
degrees. This scale was similar to that derived for another large
population-based cohort in Bristol, the Avon Longitudinal
Study of Parents and Children.
(14,15) Data were also collected
on current housing tenure. Data on current height and weight
were collected by self-completion questionnaires. As previously
published,
(13) a random 5% subsample of self-completion
questionnaires was validated against electronic general practice
records and in general there was good agreement.
Randomization and masking
After baseline data collection, participants were electronically
randomized in a 2:1 ratio in favor of controls. Randomization was
stratified by baseline osteoporosis medication prescription, and
used block sizes of 6, 9, and 12. Participants’ GPs were blinded as
to which arm their patient had been assigned. Trial coordination,
follow-updatacollection,coding,anddataentrywasdoneunder
masked conditions, as was analysis.
Intervention
All participants received a ‘‘healthy bones’’ leaflet giving
information on healthy lifestyles to maintain bone health and
reduce falls. Those allocated to the intervention arm were
additionally invited to their general practice for a 20-minute
appointment with our research nurse trained clinically to the
level of a practice nurse. During this appointment, data was
collected on the four clinical risk indicators identified in our
previous study: height loss, history of previous non-VF, Margolis
back pain score, and rib-to-pelvis distance.
(12) If the calculated
risk score was below 4 (our predetermined threshold),
participants were identified as being at high risk of a prevalent
VF, and offered a thoracolumbar radiograph at the nearest
hospital. It had been arranged that the radiographs would be
reported using standard National Health Service (NHS) reporting
techniques and the report would be sent back to the individual
participant’sGPforfurtheraction.Thismeantthattheinteraction
between the study team and GPs was limited to a meeting at
original recruitment of the practice, and provision of information
on appropriate management of prevalent VFs. No further
communicationwasmadebetweenresearchersandGPs:instead
usual NHS mechanisms for reporting results were used to mimic
any future real-life situation.
Follow-up assessment
Every 6 months after enrollment, questionnaires were posted to
all the participants asking about new prescription of osteoporo-
sis medications and new fractures.
Outcomes
The primary outcome was self-reported new prescription of
medications for treating osteoporosis, assessed at the 6-month
follow-up. No false-positive or false-negative self-reported
osteoporosis medication prescriptions were identified on the
random 5% subsample verified against electronic records.
Secondary outcome was self-reported new fractures at 6-month
and 12-month follow-up, along with new prescription of
medications for treating osteoporosis at the later time point.
No single individual could contribute more than one fracture to
this secondary outcome.
Statistical analysis
The planned sample size (n¼3860) was based on a power of
80% and a 5% significance level, but actual recruitment was
3200. However, in reality, baseline osteoporosis medication
prescribing was 7.3 per 100 women, increasing to 9.9 per
100 women. A post hoc power calculation shows that we still
have an 80% power to detect this increase (one-tail test).
Statistical analyses were performed (by E.C.) using Stata version
11 (StataCorp, LP, College Station, TX, USA). Intention to treat
analyses were used for analysis of the primary and secondary
outcomes. Screening effects were presented as differences in
percentages of women with new prescriptions for osteoporosis
medications or fractures, and compared by study arm using
chi-square tests. Odds ratios for new prescription of osteoporosis
medications or fractures for those in the screening arm were
calculated using logistic regression. The number needed to
screen to give one additional prescription was calculated
from the usual equation of the reciprocal of the risks of these
outcomes in the control minus the screening arm.
Results
A total of 8224 eligible women were identified. Of these,
1144 were not invited to take part by their GP as it was felt to
be inappropriate (medical, psychological, or social reasons)
(see Fig. 1). Of the 7080 women invited, 3200 were enrolled
(38.9%ofeligibleor45.2% ofinvited)betweenOctober2007and
May 2009, and were assigned to the control arm (n¼2138) or
screening (n¼1062). No data is available on those who declined
to take part. Baseline characteristics of participants in the two
arms are shown in Table 1. No differences were seen. Median
age of participants was 72.1 years (interquartile range [IQR],
69.0–76.1).
Trial compliance was generally good, with 92.6% of the
screening arm attending the assessment (see Fig. 1). However, of
those identified to be at high-risk of VFs (n¼401), 22.7% (n¼91)
did not attend for spinal radiographs (see Fig. 2). The main
reason given for nonattendance was the distance needed to
travel to the hospital. Of the 310 thoracolumbar radiographs
performed 230 (74.2%) werereported as showing noevidence of
VFs, 52 (16.8%) were reported as possible VFs (using wording
such as ‘‘probably a little loss of height,’’ ‘‘possible wedging of
a couple of vertebrae,’’ and ‘‘minor depression of the superior
endplate’’), and 28 (9.0%) were reported as showing definite VFs.
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medications 92.2% (n¼979) of the screening arm and 90 8%
(n¼1942) of the control arm returned the 6-month follow-up
questionnaire. The 12-month follow-up was completed by 89.8%
(n¼1920) and 90.3% (n¼959), for the control and screening
arms, respectively.
At the 6-month follow-up, allocation to screening increased
the odds of prescription of osteoporosis medications by 124%
(odds ratio [OR] for prescription 2.24; 95% confidence interval
[CI],1.16–4.33;p¼0.016)(seeTable2).Between6and12months
no differences were seen in prescription of osteoporosis
medications. There was an association between the presence
of VF on the radiograph report (see Table 3 and Fig. 2) and
prescription of osteoporosis medication. However, only 26.3%
(n¼21) of those with definite or possible VFs had been
prescribed osteoporosis medication by 6 months: 17.3% of
Table 1. Demographic and Baseline Characteristics of Participants Randomized to Control and Screening
Control group
(n¼2138) mean (SD)
Screening arm
(n¼1062) mean (SD)
p Value for
difference
Age (years) 72.6 (4.3) 72.7 (4.3) 0.691
Current height (cm) (n¼2855) 160.1 (6.6) 160.2 (6.4) 0.582
Current weight (kg) (n¼3041) 69.4 (13.5) 69.4 (12.6) 0.999
Control group
n (%)
Screening arm
n (%)
p Value for
difference
Educational qualifications (n¼2896) 0.281
None/basic matriculation 786 (40.5) 400 (41.9)
Vocational 487 (25.1) 224 (23.5)
O-levels of equivalent 329 (16.9) 184 (19.3)
A-levels or equivalent 229 (11.8) 95 (10.0)
University 111 (5.7) 51 (5.4)
Housing tenure (n¼3012) 0.777
Owned/mortgaged 1737 (86.1) 858 (86.3)
Private rental 33 (1.6) 18 (1.8)
Council or HA rental 191 (9.5) 96 (9.7)
Sheltered, residential, or NH 57 (2.8) 22 (2.2)
Smoking (n¼3154) 0.149
Never 1108 (52.6) 581 (55.4)
Used to 841 (40.0) 382 (36.4)
Currently smoking 156 (7.4) 86 (8.2)
Baseline osteoporosis medication prescription (n¼3200) 0.923
Yes 155 (7.3) 78 (7.3)
No 1983 (92.7) 984 (92.7)
Age at menopause (n¼2942) 0.277
Less than 45 years 558 (28.4) 295 (30.3)
45 or older 1410 (71.7) 679 (69.7)
Fractures after age 50 years (n¼3199) 0.878
Yes 558 (26.1) 280 (26.4)
No 1579 (73.9) 782 (73.6)
Steroids for >3 months (n¼3025) 0.426
Yes 162 (8.0) 89 (8.9)
No 1859 (92.0) 915 (91.1)
Maternal hip fracture (n¼3150) 0.782
Yes 237 (11.3) 117 (11.2)
No 1664 (79.1) 836 (79.9)
Do not know 203 (9.6) 93 (8.9)
Falls (n¼3068) 0.155
Never 761 (36.9) 382 (37.9)
Once every few years 725 (35.2) 371 (36.8)
Once per year 256 (12.4) 132 (13.1)
Few times a year 296 (14.4) 111 (11.0)
Every month or more 23 (1.1) 11 (1.1)
HA¼housing association; NH¼nursing home.
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associated with an increased proportion of new prescriptions for
osteoporosis medications at 6 months compared to possible
reporting of a VF, or reporting of no VF (p¼0.004). Of those who
were high risk and had radiographs performed, 64.3% of women
prescribed osteoporosis medications within 6 months of starting
the study had been identified with definite or possible
osteoporotic VF according to the NHS radiograph report.
However, some new prescriptions were for women in the
intervention arm identified as not at high-risk during the
screening, and some prescriptions were for those women for
whom no VF was identified on radiograph (see Fig. 2). The
numberneededtoscreentoproduceoneadditionalprescription
for osteoporosis medications within 6 months was 92.
At 12 months no difference was seen in new fractures
between participants in the control group and those in the
screening arm (OR for fracture 0.60; 95% CI, 0.35–1.03; p¼0.063).
A total of 3.5% of the control arm (n¼75) and 2.0% (n¼21) of
thescreeningarmfracturedbetween0and12months.However,
between 6 and 12 months of follow-up allocation to screening
reduced the odds of occurrence of new fractures by 72% (OR for
fracture 0.28; 95% CI, 0.12–0.67; p¼0.004). Assessment of site of
fracture in control and intervention arms (see Table 4) suggests
most of the reduction were forearm fractures.
Interven on: healthy bones informa on leaﬂet plus 
assessment and applica on of screening tool (n=983, 92.6%) 
Iden ﬁed as high risk (n=401, 40.8% 
of assessed) and oﬀered radiograph  
Had radiograph (n=310, 77.3% of 
high risk group) 
No VF on radiograph 
report (n=230, 74.2%) 
Iden ﬁed as not at high risk (n=582, 
59.2% of assessed) 
Did not a end for radiograph (n=91, 
22.7% of high risk group) 
Possible VF on radiograph 
report (n=52, 16.8%) 
Deﬁnite VF on radiograph 
report (n=28, 9.0%) 
Started on osteoporosis medica on 
by 6 months (n=5, 2.4%) 
Started on osteoporosis medica on 
by 6 months (n=5, 10.0%) 
Started on osteoporosis medica on 
by 6 months (n=4, 14.3%) 
Started on osteoporosis medica on 
by 6 months (n=0) 
1062 randomised to interven on arm 
Started on osteoporosis medica on 
by 6 months (n=4, 0.7%) 
Started on osteoporosis medica on 
by 6 months (n=1, 1.3%)) 
Did not a end 
assessment (n=79, 7.4%) 
Fig. 2. Flow diagram of participants in the intervention arm showing numbers assessed as being at high risk, numbers who had thoracolumbar
radiographs, numbers identified with vertebral fractures (VFs), and those started on osteoporosis medication at 6 months.
Table 2. Osteoporosis Medication Prescription and Fractures in Those in the Control and Screening Arms at 6-Month and 12-Month
Follow-Up
Control arm,
n (%)
Screening arm,
n (%) OR (95% CI) p
Osteoporosis medication prescription
Within 6 months of joining the study (n¼2921) 2.24 (1.16–4.33) 0.016
Yes 17 (0.9) 19 (1.9)
No 1925 (99.1) 960 (98.1)
Between 6 and 12 months of joining the study (n¼2710) 0.99 (0.45–2.23) 0.998
Yes 18 (1.0) 9 (1.0)
No 1788 (99.0) 895 (99.0)
New fractures
Within 6 months of joining the study (n¼2921) 0.87 (0.47–1.61) 0.664
Yes 34 (1.8) 15 (1.5)
No 1908 (98.2) 964 (98.5)
Between 6 and 12 months of joining the study (n¼2703) 0.28 (0.12–0.67) 0.004
Yes 41 (2.3) 6 (0.7)
No 1752 (97.7) 904 (99.3)
CI¼confidence interval; OR¼odds ratio.
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In this first trial of a screening program for identification of
postmenopausal women with VFs we found that, compared
to the control group who were not screened, allocation to
screening doubled osteoporosis medication prescription and
appeared to reduce fractures. The increase in prescriptions were
mainly appropriate, since over one-half of new prescriptions
in the high-risk group were for those women identified with
definite or possible VFs on radiograph. These results suggest
that this method of screening for prevalent VFs, which
takes a maximum of 20minutes and can be performed by a
practice nurse, should be considered in primary care for all older
women.
Our study reports an increase in new osteoporosis medication
prescribing over the first 6 months after screening, but not
during the second 6 months. This fits with the timing of risk
factor assessment and referral for spinal radiographs. It suggests
there is a window of opportunity, in which either a patient
is appropriately prescribed osteoporosis medications or the
opportunity is lost. Although we detected an increase in
new prescriptions for osteoporosis medications by 6 months,
under 50% of those with definite VF had been treated with
osteoporosis medications over this period, despite providing
each general practice with written management protocols
for prevalent VFs. In order to mimic the real-life situation in
which screening was rolled-out by practice nurses, we used a
‘‘hands-off’’ approach with minimal interaction between the
research team and GPs. It is well-recognized that changing
organizational culture such as that within primary care to
improve healthcare performance is challenging,
(16) and the large
care gap we report is similar to that seen with other general
practice–based interventions for osteoporosis management.
(17)
Future implementation of this screening program needs to focus
carefully on the response to the radiology report, highlighting
this as a key time-point in appropriate management of women
with VFs.
The reduction in fractures between 6 and 12 months was
unexpected as we were not powered to identify the expected
fracture reduction with osteoporosis medication, and this may
be a chance finding, although the overall 12-month reduction
in fractures approached statistical significance. However,
the reduction seen was in forearm and ‘‘other’’ fractures, two
categories of fracture whose risk is generally not affected by use
of bisphosphonates. Nonetheless, temporally it is plausible that
our screening arm contributed to this reduction, perhaps with a
combination of increased osteoporosis medication prescribing
and other changes such as increased prescribing of calcium and
vitamin D which may reduce falls.
(18) An alternative explanation
is that allocation to the screening arm changed behavior in the
Table 3. Prescription of Osteoporosis Medications and Presence of Vertebral Fracture on Thoracolumbar Radiograph Report
Presence of vertebral fracture on
radiograph report (n¼310)
p Value for
difference
No
(n¼230)
Possible
(n¼52)
Yes
(n¼28)
On osteoporosis medications at baseline 0.007
Yes 22 (9.6) 4 (7.7) 8 (28.6)
No 208 (90.4) 48 (92.3) 20 (71.4)
New prescription of osteoporosis medication by 6 months 0.004
Yes 5 (2.4) 5 (10.0) 4 (14.3)
No 208 (97.7) 45 (90.0) 24 (85.7)
New prescription of osteoporosis medication between 6 and 12 months 0.167
Yes 1 (0.5) 1 (2.3) 1 (4.8)
No 194 (99.5) 43 (97.7) 20 (95.2)
Values are n (%).
Table 4. Observed Fractures in the Control Arm Compared With Observed and Expected Fractures in the Screening Arm in the First
12 Months
Control arm (n¼2138) Screening arm (n¼1062)
Observed fractures, n (%) Observed fractures, n (%) Expected fractures, n
No fractures 2063 (96.49) 1041 (98.0) 1025
Total fractures 75 (3.51) 21 (1.98) 37
Forearm fractures 29 (1.36) 6 (0.57) 14
Hip fractures 6 (0.28) 3 (0.28) 3
Vertebral fractures 6 (0.28) 1 (0.10) 3
Other fractures 34 (1.59) 11 (1.04) 17
Expected fractures were calculated using the proportions found in the control arm. Fracture data was self-reported by participants.
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through fear of fractures due to risk of osteoporosis. However,
we feel this is unlikely as a qualitative Interpretative Pheno-
menological Analysis (IPA) of semistructured interviews with
10 women within the screening arm who were found to be at
high risk of VF suggests behavior was not affected.
(19)
Strengths and limitations
To our knowledge, this is the only RCT of a population-based
screening program for identification of women with prevalent
VFs. In addition, despite the large size of the study population,
the tool was simple and quick to perform, and could easily be
carried out by a trained nurse. Furthermore, the participants
invited to the study were done so on the basis of their age with
no exclusion criteria. However, the recruited study cohort only
included 38.9% of the eligible women. This likely bias may have
implications for generalizability of our results. However, as with
most research involving people,
(20) the women who did not take
part in our study are likely to be at higher risk for VFs and
osteoporosis than the women who did takepart. Therefore,if the
proportion of women taking part in any future screening could
beincreasedthis islikely tomeanthat thescreeningwillbemore
effective.Otherstrengthsarethesmallproportionofparticipants
lost to follow-up, and the analysis of end-points by researchers
blinded to screening allocation.
Our follow-up was for a relatively short duration due to
practical and financial reasons. Nonetheless, our proxy outcome
of prescription of osteoporosis medications suggests that in the
longer term this screening tool will reduce fractures and prevent
the associated reduction in quality of life. It may also be cost-
effective: a preliminary cost-effectiveness analysis suggested a
cost per quality-adjusted life year of around £30,000, but further
modeling suggests that this would be improved considerably by
increasing the proportion of women found to have a VF who
are prescribed appropriate medication. More sophisticated
modeling is required of subsequent year-on-year benefits of
appropriate osteoporosis medication prescription. This will need
to incorporate long-term adherence rates, which in the case
of bisphosphonates are relatively low,
(21) but may be higher
following use of newer parenteral therapies such as zoledronic
acid or denosumab.
(22) Ideally, reduction in fractures would be a
primary end-point, but this requires large trials of long duration
(perhaps 5 to 10 years).
Another limitation is use of self-reported osteoporosis
medication prescription and fractures. However, in the 5%
random subsample compared against electronic general
practice records these data do not suffer any nonrandom
misclassification.
(13) Any errors in self-reporting are likely to
reduce the strength of any association found toward the null,
rather than produce a spurious result. Also, thoracolumbar
radiographs impart a dose of radiation equivalent to a year’s
background radiation, and although one in four women we
X-rayed were identified with a possible or definite VF it is
important toconsider thisradiationexposuretothe75%without
VF. Alternative methods of imaging for VF are available such as
lateral DXA (VFA), but while imparting lower radiation doses they
are less easy to interpret than traditional radiographs because of
poorer image quality. Finally, although our screening tool had a
predictive value of 0.88 (significantly higher than the World
Health Organization’s Fracture Risk Algorithm [FRAX] score,
(23)
at around 0.7), it identifies all women with multiple VFs and
approximately one-half of those with one VF, rather than all
women with VFs.
Comparison with other trials
NoothertrialsofscreeningtoolsforVFshavebeenidentified.We
are aware of no national screening programs in place in any
country across the world. However, many areas of the UK have
local Fracture Liaison Services (FLS). The general aim of FLS is
to help target osteoporosis treatments at patients with the
highest absolute risk of fracture in order to maximize the cost-
effectiveness of the service.
(24) The key subgroup of people
targeted by FLS are those who present with a fracture, usually to
secondary care. However, less than one-third of VFs present
clinically,
(11,25) so FLS usually miss those with VFs as their first
presentation of osteoporosis. Our screening tool could therefore
run alongside FLS.
There is increasing interest in developing screening tools for
osteoporosis more generally, as shown by the recent emergence
of risk assessment tools such as the World Health Organization’s
FRAX.
(23) FRAX is an online tool developed to allow calculation of
an individual’s absolute risk of hip or other major osteoporotic
fracture over the next 10 years. However, once age and femoral
neckbonemineraldensity(BMD)areknown,theadditionaleight
risk factors used in FRAX do not significantly improve the
prediction of VFs over the next 4 years.
(26) Our screening tool
therefore provides an additional method of identifying those at
risk of osteoporosis and future fracture.
Conclusion and policy implications
In conclusion, compared with use of an information leaflet, our
screening tool for VFs increased new osteoporosis medication
prescription over the initial 6 months, followed by a decrease
in risk of fracture over the subsequent 6 months. However,
educational initiatives may be required to improve GPs’
understanding of the need to prescribe osteoporosis medication
after identification of a VF, if maximal benefit is to be obtained.
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